Thermo Scientific and Genedata Join Forces to Accelerate MS-Based Metabolomics Research
News Jul 15, 2008
Thermo Fisher Scientific Inc. and Genedata announced the integration of Thermo Scientific mass spectrometry (MS) instrumentation and Genedata Expressionist® to process and analyze large volumes of high-quality MS data, enabling researchers to process hundreds of gigabytes of data simultaneously.
This capability is particularly beneficial for metabolomics researchers who need to classify samples and identify metabolic profiles related to important biological phenotypes.
Genedata Expressionist performs high-throughput processing and automated quality analysis of MS-based metabolomics and proteomics data, enabling researchers to process hundreds of gigabytes of data simultaneously. Genedata Expressionist also includes a sophisticated statistical analysis platform that allows for data comparison. This integrated approach helps researchers to understand the action of all biological molecules in a single, comprehensive system.
Combining Thermo Scientific MS systems with Genedata software solutions, small molecule biomarker detection can be enhanced with an "end-to-end" system that encompasses complete scientific workflows.
Dr. Rohan Thakur, director of marketing, small molecule solutions, life sciences mass spectrometry, Thermo Fisher Scientific, explains, “Thermo Scientific instrumentation is ideally suited for metabolomics applications. The unmatched data quality resulting from high-resolution and accurate mass, coupled with the data processing power of Genedata Expressionist, will serve to simplify the search for answers in a fundamentally complex experiment. We believe this powerful combination of hardware and software will enable metabolomics researchers to solve problems faster.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE